Molecular Data Inc., through its subsidiaries, operates in the chemical e-commerce business in the People’s Republic of China.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.31|
|52 Week High||US$0.27|
|52 Week Low||US$2.23|
|1 Month Change||9.24%|
|3 Month Change||-53.71%|
|1 Year Change||-72.64%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-94.24%|
Recent News & Updates
|MKD||US Online Retail||US Market|
Return vs Industry: MKD underperformed the US Online Retail industry which returned -6.1% over the past year.
Return vs Market: MKD underperformed the US Market which returned 31.1% over the past year.
Stable Share Price: MKD is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 16% a week.
Volatility Over Time: MKD's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Molecular Data Inc., through its subsidiaries, operates in the chemical e-commerce business in the People’s Republic of China. The company operates technology-driven platform that connects participants along the chemical value chain through its integrated solutions. It delivers e-commerce solutions, financial solutions, warehousing and logistics solutions, and software-as-a-service suites for participants in the traditional chemical industry.
Molecular Data Fundamentals Summary
|MKD fundamental statistics|
Is MKD overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|MKD income statement (TTM)|
|Cost of Revenue||CN¥4.62b|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-1.49|
|Net Profit Margin||-5.54%|
How did MKD perform over the long term?See historical performance and comparison
Is Molecular Data undervalued compared to its fair value and its price relative to the market?
In this section, we usually try to help investors determine whether Molecular Data is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Molecular Data has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
How is Molecular Data forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted Retail industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Molecular Data has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Molecular Data performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MKD is currently unprofitable.
Growing Profit Margin: MKD is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MKD is unprofitable, and losses have increased over the past 5 years at a rate of 17.1% per year.
Accelerating Growth: Unable to compare MKD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MKD is unprofitable, making it difficult to compare its past year earnings growth to the Online Retail industry (62%).
Return on Equity
High ROE: MKD's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
How is Molecular Data's financial position?
Financial Position Analysis
Short Term Liabilities: MKD has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: MKD has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: MKD has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: MKD's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if MKD has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if MKD has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Molecular Data current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MKD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MKD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MKD's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MKD's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MKD's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Steven Foo (49 yo)
Mr. Steven Foo serves as the Chief Financial Officer at Molecular Data Inc. since December 01, 2020 and serves as its Chief Executive Officer since May 14, 2021. Mr. Foo had been Executive Director of Chin...
Experienced Board: MKD's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 32.6%.
Molecular Data Inc.'s employee growth, exchange listings and data sources
- Name: Molecular Data Inc.
- Ticker: MKD
- Exchange: NasdaqCM
- Founded: 2013
- Industry: Internet and Direct Marketing Retail
- Sector: Retail
- Market Cap: US$54.089m
- Shares outstanding: 171.93m
- Website: https://www.molbase.cn
Number of Employees
- Molecular Data Inc.
- Building 15
- 11th Floor
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/22 23:11|
|End of Day Share Price||2021/10/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.